Skip to main
CODX

Co-Diagnostics (CODX) Stock Forecast & Price Target

Co-Diagnostics (CODX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Co-Diagnostics Inc's promising outlook is bolstered by the expanding market for respiratory infectious disease diagnostics, particularly in the Middle East, driven by significant investments in the Kingdom of Saudi Arabia. The company’s strategic partnership with Arabian Eagle Manufacturing to commercialize its Co-Dx technologies across 19 nations positions it favorably for growth in a region with high demand for affordable molecular diagnostics. Furthermore, Co-Diagnostics is enhancing its Co-Dx PCR platform, indicating a commitment to innovation and regulatory compliance, which could further broaden its market opportunities beyond tuberculosis.

Bears say

Co-Diagnostics Inc faces multiple risks that contribute to a negative financial outlook, including potential failures in clinical evaluations and difficulty in securing necessary regulatory clearances for its products, which could hinder market entry. Additionally, the company reported significantly low revenue of $145,000 for the third quarter of 2025, alongside a substantial net loss of $5.9 million, translating to a loss of $0.16 per share, indicating ongoing financial struggles. Concerns about further dilution due to the need for additional funding at possibly unfavorable terms further exacerbate the perception of financial instability within the company.

Co-Diagnostics (CODX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Co-Diagnostics (CODX) Forecast

Analysts have given Co-Diagnostics (CODX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Co-Diagnostics (CODX) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Co-Diagnostics (CODX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.